Market Cap 33.85B
Revenue (ttm) 363.71M
Net Income (ttm) -913.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -251.24%
Debt to Equity Ratio 0.43
Volume 1,111,000
Avg Vol 2,142,046
Day's Range N/A - N/A
Shares Out 211.38M
Stochastic %K 36%
Beta 1.03
Analysts Strong Sell
Price Target $172.59

Company Profile

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 977 9900
Address:
700 US Highway 202/206, Bridgewater, United States
kelrock90
kelrock90 Oct. 24 at 4:27 PM
$INSM http://finance.yahoo.com/news/analysts-estimate-insmed-insm-report-140008725.html Thoughts?
1 · Reply
JoeB07
JoeB07 Oct. 24 at 2:04 PM
$INSM $PLTR $NVDA INSM about to beat both PLTR and NVDA to $200! It's going to be close...
0 · Reply
Zinsinus
Zinsinus Oct. 24 at 1:51 PM
$INSM Really solid non product news today. Happy employees produce results.
0 · Reply
JoeB07
JoeB07 Oct. 24 at 1:21 PM
$INSM Release the bolus! 4 trading days until Q3 results.
0 · Reply
pianoman439
pianoman439 Oct. 23 at 8:04 PM
$INSM nice accumulation today!
0 · Reply
JoeB07
JoeB07 Oct. 22 at 4:14 PM
$INSM only 5 more trading days until Q3 results...
1 · Reply
Zinsinus
Zinsinus Oct. 22 at 2:46 PM
$INSM Down 4$ on 200k shares Do they need shares?
1 · Reply
Zinsinus
Zinsinus Oct. 22 at 1:29 PM
$INSM 10:20 CT = COPD presentation today. Throw some more wood on the 🔥
0 · Reply
JoeB07
JoeB07 Oct. 22 at 1:27 PM
$INSM more from CHEST 2025
0 · Reply
pianoman439
pianoman439 Oct. 22 at 1:26 PM
$INSM EMA poised…
0 · Reply
Latest News on INSM
Insmed To Present at September Investor Conferences

Aug 21, 2025, 7:00 AM EDT - 2 months ago

Insmed To Present at September Investor Conferences


Lung Disease-Focused Insmed 'Must-Own' Name For Investors

Aug 20, 2025, 2:46 PM EDT - 2 months ago

Lung Disease-Focused Insmed 'Must-Own' Name For Investors


Josh Brown's Best Stocks in the Market: Insmed

Aug 19, 2025, 1:04 PM EDT - 2 months ago

Josh Brown's Best Stocks in the Market: Insmed


US FDA approves Insmed's lung disease drug

Aug 12, 2025, 11:42 AM EDT - 2 months ago

US FDA approves Insmed's lung disease drug


Insmed Incorporated (INSM) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 10:20 PM EDT - 2 months ago

Insmed Incorporated (INSM) Q2 2025 Earnings Call Transcript


Is Insmed Stock Overvalued After The 45% Jump?

Jun 16, 2025, 5:05 AM EDT - 4 months ago

Is Insmed Stock Overvalued After The 45% Jump?


Insmed: Company Presses On With Further POC PAH Treatment Data

Jun 10, 2025, 4:30 PM EDT - 4 months ago

Insmed: Company Presses On With Further POC PAH Treatment Data


Insmed's blood pressure drug meets main goal in mid-stage trial

Jun 10, 2025, 7:25 AM EDT - 4 months ago

Insmed's blood pressure drug meets main goal in mid-stage trial


Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript

May 8, 2025, 2:55 PM EDT - 6 months ago

Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript


Insmed: Poised For Transformation Beyond ARIKAYCE

Apr 25, 2025, 11:58 AM EDT - 6 months ago

Insmed: Poised For Transformation Beyond ARIKAYCE


Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 12:50 PM EST - 8 months ago

Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript


Insmed To Present at March 2025 Investor Conferences

Feb 11, 2025, 8:00 AM EST - 9 months ago

Insmed To Present at March 2025 Investor Conferences


kelrock90
kelrock90 Oct. 24 at 4:27 PM
$INSM http://finance.yahoo.com/news/analysts-estimate-insmed-insm-report-140008725.html Thoughts?
1 · Reply
JoeB07
JoeB07 Oct. 24 at 2:04 PM
$INSM $PLTR $NVDA INSM about to beat both PLTR and NVDA to $200! It's going to be close...
0 · Reply
Zinsinus
Zinsinus Oct. 24 at 1:51 PM
$INSM Really solid non product news today. Happy employees produce results.
0 · Reply
JoeB07
JoeB07 Oct. 24 at 1:21 PM
$INSM Release the bolus! 4 trading days until Q3 results.
0 · Reply
pianoman439
pianoman439 Oct. 23 at 8:04 PM
$INSM nice accumulation today!
0 · Reply
JoeB07
JoeB07 Oct. 22 at 4:14 PM
$INSM only 5 more trading days until Q3 results...
1 · Reply
Zinsinus
Zinsinus Oct. 22 at 2:46 PM
$INSM Down 4$ on 200k shares Do they need shares?
1 · Reply
Zinsinus
Zinsinus Oct. 22 at 1:29 PM
$INSM 10:20 CT = COPD presentation today. Throw some more wood on the 🔥
0 · Reply
JoeB07
JoeB07 Oct. 22 at 1:27 PM
$INSM more from CHEST 2025
0 · Reply
pianoman439
pianoman439 Oct. 22 at 1:26 PM
$INSM EMA poised…
0 · Reply
JoeB07
JoeB07 Oct. 21 at 9:09 PM
$INSM more evidence....
1 · Reply
NightBreeze
NightBreeze Oct. 21 at 3:45 PM
$INSM In $129, out $165. Surpassed initial $150 goal. GL longs. Will be buying any dips
2 · Reply
JoeB07
JoeB07 Oct. 21 at 2:51 AM
$INSM ​it's going to be a launch for the record books. The patient bolus is vast. We've known this for years as many drug companies have trialed NCFB drugs for years without success. A 200 year old diagnosis with no approved treatments....
0 · Reply
JoeB07
JoeB07 Oct. 20 at 9:14 PM
$INSM $LQDA $UTHR $VRTX granted this is a sample size. Key data- these pulmonologists each wrote an average of 9x prescriptions which covered 10% of their patients. So in this sample 10% of eligible NCFB patients got a prescription in the first month post launch? That's pretty d8mn impressive. Imagine how many more they will reach in Q4. Excited to see Q4 numbers at JPM in January....
1 · Reply
Quantumup
Quantumup Oct. 20 at 6:59 PM
UBS reiterated $INSM at a Buy rating and a $194 price target. $LQDA $UTHR UBS said: We see more upside to the Brinsupri story in NCFB, following our KOL checks and survey results (n=29) with pulmonologists that manage ~2.8K NCFB patients with confirmed diagnosis by CT scan. We are doing a KOL call on Brinsupri launch on 10/21, 2pm ET. While our survey accounts for less than 1% of NCFB patients with >2 exacerbations, surveyed physicians noted 278 prescriptions written through September 2025. With the caveat that our physician checks indicate it can take 2-4 weeks for patients to initiate therapy following the initial prescription, we think these results are supportive of rapid uptake. Within 5 years post launch, surveyed physicians expect to treat >1,400 NCFB patients. Our estimates for Brinsupri peak market share in the US of 35% and $6.5BN worldwide peak sales for Brinsupri in NCFB remain unchanged.
0 · Reply
pianoman439
pianoman439 Oct. 20 at 2:06 PM
$INSM Insmed (NASDAQ:INSM) is now covered by Wells Fargo & Company (star star star blank star blank star) (analyst Tiago Fauth). They set an "overweight" rating and a $171.00 price target on the stock. This represents a 3.2% upside from the current price of $165.76
0 · Reply
pianoman439
pianoman439 Oct. 20 at 11:57 AM
$INSM last time I had a substantial gain in a company with a comparable market value was Apple Computer. Its Market Cap is now 3.7 Trillion. I should’ve never sold, and I’m not making that mistake with Insmed.
1 · Reply
Estimize
Estimize Oct. 20 at 10:20 AM
Wall St is expecting -1.34 EPS for $INSM Q3 [Reporting 10/30 BMO] http://www.estimize.com/intro/insm?chart=historical&metric_name=eps&utm_c
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 20 at 8:09 AM
Enter: $INSM NOV 21 2025 $170 CALLS Buy in Price: $8.20 - $8.30 Take Profit: $16.77 Stop Bleeding: $7.30 ROI Potential: 102% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
bemore
bemore Oct. 19 at 2:13 PM
$INSM Presentations will feature new prespecified and post-hoc subgroup analyses from the Phase 3 ASPEN trial evaluating brensocatib in patients with non-cystic fibrosis bronchiectasis (NCFB). Highlights include data showing suppression of neutrophil serine proteases (NSPs), as well as late-breaking results demonstrating effects on structural lung changes from a high-resolution CT substudy. Additional presentations feature new insights into treatment outcomes among patients with comorbid chronic obstructive pulmonary disease (COPD), clinical findings in Asian populations, and detailed assessments of symptom burden using the Bronchiectasis Exacerbation and Symptom Tool (BEST), both during and outside of pulmonary exacerbation events. Together, these analyses further explore BRINSUPRI's mechanism of action and its potential impact on disease management. Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025 PR Newswire
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 18 at 11:30 AM
Enter: $INSM NOV 21 2025 $170 CALLS Buy in Price: $7.80 - $7.84 Take Profit: $14.66 Stop Bleeding: $6.90 ROI Potential: 87% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
JoeB07
JoeB07 Oct. 17 at 9:56 PM
$INSM 8x trading days left until earnings. Expecting an update on how the launch is proceeding and an update on how many prescriptions in the first 45 days. BiRCH trial ends sometime between 30OCT and 20NOV. Results by end of year. I expect W.Lewis will specify during the EC a window in November or December when the results will be announced. Outside of efficacy, investors will pay particular attention to the safety of the new 40mg dose being trialed.
2 · Reply